No items found.
Left chevron

Go Back

Pharmacology

SGLT2 Inhibitors (eg, Empagliflozin) for Diabetes: Pharmacology Review

SGLT2 inhibitors pharmacology review: Mechanisms, type 2 diabetes benefits, side effects, and cardiorenal outcomes.

Video thumbnail

To view this video, please enable marketing cookies from Cookie Preferences in the footer.

Horizontal dot pattern

SGLT2 inhibitors (bexagliflozin,canagliflozin,dapagliflozin,empagliflozin,ertugliflozin) don’t just lower glucose and A1C, but these meds have become relevant in cardiovascular disease and chronic kidney disease in the right patients also with type 2 diabetes (T2DM). In this lecture from This is Why, Dr. Busti will make the SGLT2 inhibitors make sense as they provide cardiorenal protection above their improvements in A1C.

You’ll learn how to:
- Mechanism of action (MOA): how SGLT2 blockade drives glucosuria, modest A1c reduction, weight loss, and BP lowering
- Clinical use: where SGLT2 inhibitors fit for type 2 diabetes, plus major outcomes in heart failure and chronic kidney disease (CKD) (cardiorenal protection is a key reason they’re prioritized in modern guidelines)
- Key drugs (for exams + real-world practice): Empagliflozin (Jardiance), Dapagliflozin (Farxiga), Canagliflozin (Invokana), Ertugliflozin (Steglatro), and Bexagliflozin (Brenzavvy)
- Adverse effects & safety pearls: genital mycotic infections, volume depletion/hypotension, AKI considerations, and the “don’t-miss” rare events like euglycemic DKA (plus how to recognize it)

The goal = make medical education easy and clinically relevant.

Chapter Table of Contents
01:44 - Agents
02:53 - Indications & Uses
05:37 - Net Benefit
06:59 - Pharmacology
13:33 - Clinical Knowledge
33:25 - Summary

If this helped you, please like, subscribe to our YouTube Channel, and share it with a classmate or colleague. That will help this new channel continue producing free, high-yield medical education content.

Don’t forget to turn on notifications on YouTube so you don’t miss upcoming lectures in pharmacology, medical rounds, and more!

#sglt2inhibitors #empagliflozin #type2diabetes #diabetespharmacology #busti

Disclaimer:
This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.

This is why - membership

More than just access—it’s where understanding deepens.

Create a free account or log in to gain access to this content!

Dot pattern graphic

Dive Deeper

Bonus Video (ad free)

Deep Dive video thumbnail

To view this video, please enable marketing cookies.

Downloads

Antidiabetic Agents Lecture Tables

Dive Deeper

Bonus Video

Downloads

Antidiabetic Agents Lecture Tables